The Usher Syndrome Market is estimated at US$2.3 billion in 2026 and is projected to grow at a CAGR of 4.7% to reach US$3.3 billion by 2034.
Core applications include genetic diagnosis, hearing support, vision monitoring, counseling services, rare disease research, and experimental gene based therapeutic development. Demand reflects the need for earlier diagnosis, growing rare disease awareness, advances in gene therapy research, and demand for integrated hearing and vision support in specialist.
This product will be delivered within 1-3 business days.
Market Overview
The Usher Syndrome Market covers diagnostic, supportive care, genetic testing, and emerging treatment activities focused on Usher syndrome across rare disease, audiology, and ophthalmology pathways. Its value chain includes diagnostic labs, genetic testing firms, specialty clinics, hearing device suppliers, research institutions, biotech developers, and patient advocacy groups.Core applications include genetic diagnosis, hearing support, vision monitoring, counseling services, rare disease research, and experimental gene based therapeutic development. Demand reflects the need for earlier diagnosis, growing rare disease awareness, advances in gene therapy research, and demand for integrated hearing and vision support in specialist.
Key Companies Analysed
- Blueprint Genetics
- Invitae
- Illumina
- Thermo Fisher Scientific
- Roche
- GeneDx
- Natera
- Quest Diagnostics
- Labcorp
- Iveric Bio
- ProQR Therapeutics
- Atsena Therapeutics
- Editas Medicine
- Sana Biotechnology
- Biogen
- Spark Therapeutics
- Novartis
- Regeneron
- Pfizer
- MeiraGTx
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Usher Syndrome Market Overview
3. Usher Syndrome Market Dynamics
4. Usher Syndrome Market Strategic Analysis
5. Global Usher Syndrome Market Size, Share and Forecast, 2025-2034
6. North America Usher Syndrome Market Outlook to 2034
7. Europe Usher Syndrome Market Outlook to 2034
8. Asia-Pacific Usher Syndrome Market Outlook to 2034
9. Middle East and Africa Usher Syndrome Market Outlook to 2034
10. South and Central America Usher Syndrome Market Outlook to 2034
11. Usher Syndrome Market Competitive Landscape
12. Appendix
Companies Mentioned
- Blueprint Genetics
- Invitae
- Illumina
- Thermo Fisher Scientific
- Roche
- GeneDx
- Natera
- Quest Diagnostics
- Labcorp
- Iveric Bio
- ProQR Therapeutics
- Atsena Therapeutics
- Editas Medicine
- Sana Biotechnology
- Biogen
- Spark Therapeutics
- Novartis
- Regeneron
- Pfizer
- MeiraGTx
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value ( USD | $ 2.3 Billion |
| Forecasted Market Value ( USD | $ 3.3 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
